Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.32 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21125082 | 0.88 | KDM4E (0.36) | HSD11B1KDM4EALDH1A1 | |
| SCHEMBL21039532 | 0.88 | HRH3 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL20330211 | 0.85 | GBA1 (0.36) | HSD11B1GBA1 | |
| SCHEMBL25728588 | 0.85 | ACHE (0.35) | HSD11B1NPC1KDM1AALDH1A1ACHE | |
| SCHEMBL21933931 | 0.84 | KDM4E (0.38) | KDM4ENPC1ALDH1A1 | |
| SCHEMBL21919415 | 0.83 | HSD11B1 (0.37) | HSD11B1GBA1MAP4K4KDM4ENPC1 | |
| SCHEMBL8149011 | 0.83 | HSD11B1 (0.47) | HSD11B1GBA1MAP4K4KDM4ENPC1 | |
| SCHEMBL4893194 | 0.83 | HSD11B1 (0.47) | HSD11B1GBA1MAP4K4KDM4ENPC1 | |
| SCHEMBL6057032 | 0.83 | — | — | |
| SCHEMBL24854090 | 0.83 | CYP2D6 (0.36) | HSD11B1KDM4EALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338371-A1 | PHARMACEUTICAL COMPOSITIONS OF PROTAC COMPOUNDS AND USES THEREOF | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230131830-A1 | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-04-27 | — | — | US | disclosed |
| US-20230131830-A1 | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-04-27 | — | — | US | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220220069-A1 | COMPOUND USED AS SIRT6 SMALL-MOLECULE ALLOSTERIC ACTIVATOR AND PHARMACEUTICAL COMPOSITION THEREOF | SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-19 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080009524-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-10 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220069-A1 | COMPOUND USED AS SIRT6 SMALL-MOLECULE ALLOSTERIC ACTIVATOR AND PHARMACEUTICAL COMPOSITION THEREOF | SIRT6, SIRT1, SIRT7 | HSD11B1 3269/4885GBA1 2733/4885MAP4K4 785/4885 |
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | PDE4B, PDE4A, PDE3B | HSD11B1 437/4885GBA1 1479/4885MAP4K4 313/4885 |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | HSD11B1 3326/4885GBA1 2772/4885MAP4K4 442/4885 |
| US-20230131830-A1 | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES | TYMP, DPYD, TYMS | HSD11B1 2745/4885GBA1 1253/4885MAP4K4 2703/4885 |
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | PDE4A, PDE4B, PDE3B | HSD11B1 574/4885GBA1 1296/4885MAP4K4 219/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | HSD11B1 2924/4885GBA1 1896/4885MAP4K4 4536/4885 |
| US-20080009524-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | HSD11B1 2322/4885GBA1 363/4885MAP4K4 4714/4885 |
| US-20230338371-A1 | PHARMACEUTICAL COMPOSITIONS OF PROTAC COMPOUNDS AND USES THEREOF | ADRM1, PSMC1, UBE3C | HSD11B1 2982/4885GBA1 2384/4885MAP4K4 4272/4885 |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | HSD11B1 2145/4885GBA1 384/4885MAP4K4 4752/4885 |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | HSD11B1 2145/4885GBA1 384/4885MAP4K4 4752/4885 |
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | KRAS, NRAS, HRAS | HSD11B1 1515/4885GBA1 1986/4885MAP4K4 375/4885 |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | CFTR, ABCB4, ABCF2 | HSD11B1 2828/4885GBA1 136/4885MAP4K4 4586/4885 |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | HSD11B1 1845/4885GBA1 3907/4885MAP4K4 2966/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | HSD11B1 3024/4885GBA1 3785/4885MAP4K4 2120/4885 |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HSD11B1 802/4885GBA1 1086/4885MAP4K4 1676/4885 |
| US-20070265260-A1 | Quinazoline derivatives | TYK2, ROR1, JAK1 | HSD11B1 1008/4885GBA1 2404/4885MAP4K4 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.